Generic Kengreal Availability
Last updated on Sep 10, 2025.
Kengreal is a brand name of cangrelor, approved by the FDA in the following formulation(s):
KENGREAL (cangrelor - powder;intravenous)
Is there a generic version of Kengreal available?
A generic version of Kengreal has been approved by the FDA. However, this does not mean that the product will necessarily be commercially available - possibly because of drug patents and/or drug exclusivity. The following products are equivalent to Kengreal and have been approved by the FDA:
cangrelor powder;intravenous
-
Manufacturer: GLAND
Approval date: August 11, 2025
Strength(s): 50MG/VIAL [AP]
Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Kengreal. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.
See also: Generic Drug FAQ.
Related patents
Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.
-
Pharmaceutical formulations comprising high purity cangrelor and methods for preparing and using the same
Patent 10,039,780
Issued: August 7, 2018
Inventor(s): Dutta Panna & Rafai Far Adel & Ding Min & Motheram Rajeshwar
Assignee(s): Chiesi Farmaceutici S.p.A.The present invention relates to high purity cangrelor, pharmaceutical formulations comprising high purity cangrelor as an active ingredient, methods for preparing such compounds and formulations, and methods for using the pharmaceutical formulations in the inhibition of platelet activation and aggregation.
Patent expiration dates:
- July 10, 2035✓
- July 10, 2035
-
Methods of treating, reducing the incidence of, and/or preventing ischemic events
Patent 8,680,052
Issued: March 25, 2014
Inventor(s): Arculus-Meanwell Clive Arthur & Skerjanec Simona & Prats Jayne & Schneider David J.
Assignee(s): The Medicines CompanyMethods of treating, reducing the incidence of, and/or preventing an ischemic event in a patient undergoing percutaneous coronary intervention (PCI), comprising administering to the patient a pharmaceutical composition comprising cangrelor. The method may further comprise administering an additional therapeutic agent to the patient, the additional therapeutic agent comprising a P2Yinhibitor. Pharmaceutical compositions useful for treating, reducing the incidence of, and/or preventing an ischemic event in a patient undergoing PCI. The pharmaceutical compositions comprise cangrelor. Methods of preparing a pharmaceutical composition for treating, reducing the incidence of, and/or preventing an ischemic event in a patient undergoing PCI, comprising admixing cangrelor with one or more pharmaceutically acceptable excipients. An ischemic event may include stent thrombosis, myocardial infarction, ischemia-driven revascularization, and mortality.
Patent expiration dates:
- March 9, 2033✓
- March 9, 2033
-
Pharmaceutical formulations comprising high purity cangrelor and methods for preparing and using the same
Patent 9,295,687
Issued: March 29, 2016
Inventor(s): Dutta Panna & Rafai Far Adel & Ding Min & Motheram Rajeshwar
Assignee(s): THE MEDICINES COMPANYThe present invention relates to high purity cangrelor, pharmaceutical formulations comprising high purity cangrelor as an active ingredient, methods for preparing such compounds and formulations, and methods for using the pharmaceutical formulations in the inhibition of platelet activation and aggregation.
Patent expiration dates:
- July 10, 2035✓
- July 10, 2035
-
Methods of treating, reducing the incidence of, and/or preventing ischemic events
Patent 9,427,448
Issued: August 30, 2016
Inventor(s): Arculus-Meanwell Clive Arthur & Skerjanec Simona & Prats Jayne
Assignee(s): The Medicines CompanyMethods of treating, reducing the incidence of, and/or preventing an ischemic event in a patient undergoing percutaneous coronary intervention (PCI), comprising administering to the patient a pharmaceutical composition comprising cangrelor. The method may further comprise administering an additional therapeutic agent to the patient, the additional therapeutic agent comprising a P2Yinhibitor. Pharmaceutical compositions useful for treating, reducing the incidence of, and/or preventing an ischemic event in a patient undergoing PCI. The pharmaceutical compositions comprise cangrelor. Methods of preparing a pharmaceutical composition for treating, reducing the incidence of, and/or preventing an ischemic event in a patient undergoing PCI, comprising admixing cangrelor with one or more pharmaceutically acceptable excipients. An ischemic event may include stent thrombosis, myocardial infarction, ischemia-driven revascularization, and mortality.
Patent expiration dates:
- November 10, 2030✓
- November 10, 2030
-
Pharmaceutical formulations comprising high purity cangrelor and methods for preparing and using the same
Patent 9,439,921
Issued: September 13, 2016
Inventor(s): Dutta Panna & Rafai Far Adel & Ding Min & Motheram Rajeshwar
Assignee(s): THE MEDICINES COMPANYThe present invention relates to high purity cangrelor, pharmaceutical formulations comprising high purity cangrelor as an active ingredient, methods for preparing such compounds and formulations, and methods for using the pharmaceutical formulations in the inhibition of platelet activation and aggregation.
Patent expiration dates:
- July 10, 2035✓
- July 10, 2035
-
Pharmaceutical formulations comprising high purity cangrelor and methods for preparing and using the same
Patent 9,700,575
Issued: July 11, 2017
Inventor(s): Dutta Panna & Rafai Far Adel & Ding Min & Motheram Rajeshwar
Assignee(s): Chiesi Farmaceutici, S.P.A.The present invention relates to high purity cangrelor, pharmaceutical formulations comprising high purity cangrelor as an active ingredient, methods for preparing such compounds and formulations, and methods for using the pharmaceutical formulations in the inhibition of platelet activation and aggregation.
Patent expiration dates:
- July 10, 2035✓
- July 10, 2035
-
Methods of treating or preventing stent thrombosis
Patent 9,925,265
Issued: March 27, 2018
Inventor(s): Arculus-Meanwell Clive Arthur & Skerjanec Simona
Assignee(s): Chiesi Farmaceutici S.p.A.The present invention is directed to the following: methods of treating or preventing stent thrombosis using pharmaceutical compositions comprising cangrelor and optionally bivalirudin; methods of reducing mortality in a subject undergoing stent implantation using pharmaceutical compositions comprising cangrelor and optionally bivalirudin; medicaments comprising cangrelor and optionally bivalirudin useful for treating or preventing stent thrombosis, or useful for reducing mortality in a subject undergoing stent implantation; pharmaceutical compositions comprising cangrelor and bivalirudin; and methods of preparing a medicament comprising cangrelor and optionally bivalirudin useful for treating or preventing stent thrombosis, or useful for reducing mortality in a subject undergoing stent implantation.
Patent expiration dates:
- May 13, 2029✓
- May 13, 2029
More about Kengreal (cangrelor)
- Check interactions
- Compare alternatives
- Pricing & coupons
- Side effects
- Dosage information
- During pregnancy
- FDA approval history
- Drug class: platelet aggregation inhibitors
Patient resources
Professional resources
Related treatment guides
Related/similar drugs
Glossary
| Term | Definition |
|---|---|
| Drug Patent | A drug patent is assigned by the U.S. Patent and Trademark Office and assigns exclusive legal right to the patent holder to protect the proprietary chemical formulation. The patent assigns exclusive legal right to the inventor or patent holder, and may include entities such as the drug brand name, trademark, product dosage form, ingredient formulation, or manufacturing process A patent usually expires 20 years from the date of filing, but can be variable based on many factors, including development of new formulations of the original chemical, and patent infringement litigation. |
| Drug Exclusivity | Exclusivity is the sole marketing rights granted by the FDA to a manufacturer upon the approval of a drug and may run simultaneously with a patent. Exclusivity periods can run from 180 days to seven years depending upon the circumstance of the exclusivity grant. |
| RLD | A Reference Listed Drug (RLD) is an approved drug product to which new generic versions are compared to show that they are bioequivalent. A drug company seeking approval to market a generic equivalent must refer to the Reference Listed Drug in its Abbreviated New Drug Application (ANDA). By designating a single reference listed drug as the standard to which all generic versions must be shown to be bioequivalent, FDA hopes to avoid possible significant variations among generic drugs and their brand name counterpart. |
| AP | Injectable aqueous solutions and, in certain instances, intravenous non-aqueous solutions. It should be noted that even though injectable (parenteral) products under a specific listing may be evaluated as therapeutically equivalent, there may be important differences among the products in the general category, Injectable; Injection. For example, some injectable products that are rated therapeutically equivalent are labeled for different routes of administration. In addition, some products evaluated as therapeutically equivalent may have different preservatives or no preservatives at all. Injectable products available as dry powders for reconstitution, concentrated sterile solutions for dilution, or sterile solutions ready for injection are pharmaceutical alternative drug products. They are not rated as therapeutically equivalent (AP) to each other even if these pharmaceutical alternative drug products are designed to produce the same concentration prior to injection and are similarly labeled. Consistent with accepted professional practice, it is the responsibility of the prescriber, dispenser, or individual administering the product to be familiar with a product's labeling to assure that it is given only by the route(s) of administration stated in the labeling. |
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.